Biodexa Pharmaceuticals (BDRX)
1.44
-0.10 (-6.49%)
At close: Apr 03, 2025, 3:59 PM
1.46
1.29%
After-hours: Apr 03, 2025, 07:58 PM EDT
-6.49% (1D)
| Bid | 1.41 |
| Market Cap | 2.09K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -77.52 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -85.8 |
| Analyst | n/a |
| Ask | 1.5 |
| Volume | 160,288 |
| Avg. Volume (20D) | 1,586,990 |
| Open | 1.43 |
| Previous Close | 1.54 |
| Day's Range | 1.33 - 1.49 |
| 52-Week Range | 1.14 - 74.00 |
| Beta | 1.50 |
About BDRX
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2015
Employees 21
Stock Exchange NASDAQ
Ticker Symbol BDRX
Website https://www.biodexapharma.com
2 weeks ago
+15.84%
Biodexa Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
3 weeks ago
-21.05%
Biodexa Pharmaceuticals shares are trading lower after the company announced outcome of type C meeting with FDA regarding the phase 3 program for eRapa in FAP.
